Full TitlePhase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma
Some patients with bladder cancer live longer if they receive chemotherapy before they have bladder cancer surgery. In this study, researchers want to see if this approach — called neoadjuvant chemotherapy — can be useful in patients with urothelial cancer affecting the kidney and ureter, which is similar in behavior to urothelial cancer of the bladder.
Patients will receive gemcitabine and cisplatin before surgery to see if these anticancer drugs can shrink the tumor. Other studies have shown that patients who undergo surgery to remove the kidney and ureter are often unable to receive full doses of these chemotherapy drugs after the kidney is removed because the remaining kidney function may not be sufficient to tolerate the drugs.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have high-grade transitional cell carcinoma of the upper urinary tract (kidney/ureter) and be candidates for nephrectomy (kidney removal).
- Patients may not have had prior radiation therapy or chemotherapy for their urothelial cancer.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Jonathan Coleman at 646-422-4432.